Bank Julius Baer & Co. Ltd Zurich lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 22.7% in the 4th quarter, HoldingsChannel reports. The firm owned 14,242 shares of the biopharmaceutical company’s stock after selling 4,174 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Gilead Sciences were worth $1,748,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in GILD. Ares Financial Consulting LLC bought a new stake in Gilead Sciences during the fourth quarter worth about $28,000. Financial Consulate Inc. lifted its stake in Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. lifted its stake in shares of Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 86 shares during the last quarter. MTM Investment Management LLC lifted its stake in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares during the last quarter. Finally, BOCHK Asset Management Ltd bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $31,000. Institutional investors own 83.67% of the company’s stock.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. The trade was a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,000 shares of company stock valued at $9,238,250 in the last 90 days. Insiders own 0.30% of the company’s stock.
Gilead Sciences Trading Down 1.9%
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts predict that Gilead Sciences, Inc. will post -0.78 EPS for the current year.
Gilead Sciences Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on GILD. TD Cowen boosted their target price on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Weiss Ratings raised Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, May 11th. Deutsche Bank Aktiengesellschaft boosted their target price on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Sanford C. Bernstein reissued an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada lowered their target price on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating for the company in a research note on Friday, May 8th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $157.04.
Get Our Latest Research Report on Gilead Sciences
Gilead Sciences Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Stories
- Five stocks we like better than Gilead Sciences
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
